ELUTIA INC. (ELUT) — Inside-Filings

Kritische 8-K Meldungen

WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (09.03.2026)

Datum	Meldung	Schwere	Filing	Auszug
09.03.2026	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoint
14.10.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
02.02.2024	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Stammdaten

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Unternehmen & Branche

Name	ELUTIA INC.
Ticker	ELUT
CIK	0001708527
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2836 · Biological Products, (No Diagnostic Substances)

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	42,8 Mio. USD
Beta	0,71
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	53,380,000	0.87	62,350,000	27,672,000
2025-09-30	10-Q	-3,868,000	-0.19	29,407,000	-43,918,000
2025-06-30	10-Q	-9,610,000	-0.26	33,849,000	-41,843,000
2025-03-31	10-Q	-3,933,000	-0.21	39,298,000	-36,458,000
2024-12-31	10-K	-53,949,000	-1.86	36,127,000	-46,260,000
2024-09-30	10-Q	1,286,000	-0.33	48,407,000	-40,238,000
2024-06-30	10-Q	-28,180,000	-1.13	41,904,000	-64,338,000
2024-03-31	10-Q	-17,994,000	-0.75	35,362,000	-50,299,000
2023-12-31	10-K	-37,656,000	-2.07	43,428,000	-38,600,000
2023-09-30	10-Q	-9,747,000	-0.57	54,580,000	-29,473,000
2023-06-30	10-Q	-10,621,000	-0.65	52,329,000	-22,128,000
2023-03-31	10-Q	-7,974,000	-0.49	60,630,000	-12,175,000
2022-12-31	10-K	-32,897,000	-2.38	68,841,000	-5,033,000
2022-09-30	10-Q	-9,910,000	-0.73	61,022,000	-10,681,000
2022-06-30	10-Q	-9,398,000	-0.69	52,854,000	-1,369,000
2022-03-31	10-Q	-8,149,000	-0.60	59,926,000	6,559,000
2021-12-31	10-K	-24,832,000	-2.38	67,170,000	13,521,000
2021-09-30	10-Q	-8,316,000	-0.81	59,903,000	7,859,000
2021-06-30	10-Q	-2,385,000	-0.23	69,702,000	14,967,000
2021-03-31	10-Q	-5,067,000	-0.50	74,209,000	16,444,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-01-30	NEELS GUIDO J	Director	Open Market Purchase	20,000	1.04	20,800.00	+213,3%
2026-01-29	NEELS GUIDO J	Director	Open Market Purchase	15,000	1.06	15,900.00	+163,1%
2026-01-28	NEELS GUIDO J	Director	Open Market Purchase	15,000	1.06	15,900.00	+163,1%
2025-12-17	Colpman David	Director	Open Market Purchase	12,500	0.51	6,375.00	+65,4%
2025-12-17	Mills C Randal	Director, Officer, PRESIDENT AND CEO	Open Market Purchase	3,000	0.51	1,530.00	+15,7%
2025-12-17	Ferguson Matthew	Officer, CHIEF FINANCIAL OFFICER	Open Market Purchase	60,000	0.53	31,800.00	+326,2%
2025-12-17	Makes Brigid	Director	Open Market Purchase	25,000	0.52	13,000.00	+133,3%
2025-12-02	Ferguson Matthew	Officer, CHIEF FINANCIAL OFFICER	Open Market Purchase	5,500	0.67	3,685.00	+37,8%
2025-12-01	Ferguson Matthew	Officer, CHIEF FINANCIAL OFFICER	Open Market Purchase	4,500	0.65	2,925.00	+30,0%
2025-11-24	Mills C Randal	Director, Officer, PRESIDENT AND CEO	Open Market Purchase	5,000	0.60	3,000.00	+30,8%
2025-11-17	Colpman David	Director	Open Market Purchase	15,500	0.74	11,470.00	+117,6%
2025-11-13	Mills C Randal	Director, Officer, PRESIDENT AND CEO	Open Market Purchase	5,000	0.74	3,700.00	+38,0%
2025-11-13	Mills C Randal	Director, Officer, PRESIDENT AND CEO	Open Market Purchase	5,000	0.75	3,750.00	+38,5%
2025-11-13	Mills C Randal	Director, Officer, PRESIDENT AND CEO	Open Market Purchase	3,500	0.76	2,660.00	+27,3%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.